VIII. über dermato-therapeutische Ersatzpräparate

Ledermann, R.

doi:10.1159/000248074

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 10 year overall survival rate remains <30% over the past 30 years due to the fact that the vast majority (more than 70%) of patients in clinic are diagnosed at advanced stages (stage III or stage IV) of disease with widespread dissemination in pelvic and abdominal cavity . The current first‐line treatment for ovarian cancer is debulking surgery combined with paclitaxel‐ and carboplatin‐based chemotherapy . Although many patients display a good initial response to these conventional therapies, most of them experience relapse and ultimately develop platinum resistance within 6 to 18 months .…”

Section: Introductionmentioning

confidence: 99%

Artificial Mini Dendritic Cells Boost T Cell–Based Immunotherapy for Ovarian Cancer

et al. 2020

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological malignancy with high recurrence rates and low survival rates, remaining a disease of high unmet need. Cancer immunotherapy, which harnesses the potential of the immune system to attack tumors, has emerged as one of the most promising treatment options in recent years. As an important form of immunotherapy, dendritic cell (DC)–based vaccines have demonstrated the ability to induce an immune response, while clinical efficacy of DC vaccines remains unsubstantiated as long‐term benefit is only reported in a restricted proportion of patients. Here, a biomimetic nanovaccine derived from DCs is developed through cell membrane coating nanotechnology. This nanovaccine, denoted “mini DC,” inherits the ability of antigen presentation and T cells' stimulation from DCs and is shown to elicit enhanced activation of T cells both in vitro and in vivo. In a mouse model of ovarian cancer, mini DCs exhibit superior therapeutic and prophylactic efficacy against cancer including delayed tumor growth and reduced tumor metastasis compared with DC vaccine. These findings suggest that mini DCs may serve as a facile and potent vaccine to boost anticancer immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%